Possible Association of NAT2 Polymorphism with Laryngeal Cancer Risk: an Evidence-based Meta-analysis

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2011 Aug 31

PMID 21877196

Citations 9

Authors

Xin-Jiang Ying

Pin Dong

Bin Shen

Jie Wang

Sang Wang

Guo Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: N-acetyltransferase 2 (NAT2) plays an important role in the metabolism of various potential carcinogens, which can be subdivided into rapid and slow acetylation phenotype according to the different genotypes. A number of studies have been devoted to the association of NAT2 polymorphism with susceptibility to laryngeal carcinoma; however, the results were inconsistent and inconclusive. The aim of the present study was to conduct a meta-analysis assessing the possible association of NAT2 polymorphism with laryngeal cancer risk.

Methods: The relevant studies were identified through a search of PubMed, Embase, ISI Web of Knowledge, and Chinese National Knowledge Infrastructure until February 2011 and selected on the basis of the established inclusion criteria for publications, and then a meta-analysis was performed to quantitatively summarize the association of NAT2 polymorphism with laryngeal cancer susceptibility.

Results: Seven studies were included in the present meta-analysis, which described a total of 980 laryngeal cancer cases and 1,487 controls. The overall odds ratio (OR) for NAT2 slow and rapid acetylators was 0.99 (95% CI = 0.71-1.38) and 1.01 (95% CI = 0.72-1.40), respectively. When stratifying for race, the pooled ORs for NAT2 slow acetylator were 1.99 (95% CI = 1.10-3.63) in Asians and 0.85 (95% CI = 0.62-1.15) in Caucasians, and the pooled ORs for NAT2 rapid acetylator were 0.50 (95% CI = 0.28-0.91) in Asians and 1.18 (95% CI = 0.87-1.60) in Caucasians.

Conclusions: This meta-analysis suggested that there was overall lack of association between NAT2 polymorphism and laryngeal cancer risk; however, NAT2 slow acetylation may contribute to a risk factor for laryngeal cancer in Asians but not in Caucasians.

Citing Articles

Association of Polymorphisms with Susceptibility to Head and Neck Cancers-A Meta-Analysis, Meta-Regression, and Trial Sequential Analysis.

Mohammadi H, Momeni Roochi M, Sadeghi M, Garajei A, Heidar H, Ghaderi B Medicina (Kaunas). 2021; 57(10).

PMID: 34684132 PMC: 8541135. DOI: 10.3390/medicina57101095.

Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine N-Acetyltransferase NAT2.

Conway L, Rendo V, Correia M, Bergdahl I, Sjoblom T, Globisch D Angew Chem Int Ed Engl. 2020; 59(34):14342-14346.

PMID: 32497306 PMC: 7497018. DOI: 10.1002/anie.202005915.

N-Acetyltransferase 2 (NAT2) polymorphism as a risk modifier of susceptibility to pediatric acute lymphoblastic leukemia.

Kamel A, Ebid G, Moussa H Tumour Biol. 2015; 36(8):6341-8.

PMID: 25804798 DOI: 10.1007/s13277-015-3320-7.

Glutathione S-transferase T1 null genotype and laryngeal cancer risk: a meta-analysis.

Li Q, Liu M Tumour Biol. 2014; 35(9):8781-5.

PMID: 24879623 DOI: 10.1007/s13277-014-2121-8.

N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case-control studies.

Zhang L, Xiang Z, Hao R, Li R, Zhu Y Tumour Biol. 2013; 35(4):3585-95.

PMID: 24338712 DOI: 10.1007/s13277-013-1473-9.

References

Unal M, Tamer L, Akbas Y, Pata Y, Vayisoglu Y, Degirmenci U . Genetic polymorphism of N-acetyltransferase 2 in the susceptibility to laryngeal squamous cell carcinoma. Head Neck. 2005; 27(12):1056-60. DOI: 10.1002/hed.20284. View

Hein D, Doll M, Fretland A, Leff M, Webb S, Xiao G . Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000; 9(1):29-42. View

Boccia S, Cadoni G, Sayed-Tabatabaei F, Volante M, Arzani D, De Lauretis A . CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer. J Cancer Res Clin Oncol. 2007; 134(1):93-100. DOI: 10.1007/s00432-007-0254-5. View

Rouissi K, Ouerhani S, Marrakchi R, Ben Slama M, Sfaxi M, Ayed M . Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population. Cancer Genet Cytogenet. 2009; 190(2):101-7. DOI: 10.1016/j.cancergencyto.2009.01.007. View

Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I . Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics. 1999; 9(1):103-11. View

Ambrosone C, Kropp S, Yang J, Yao S, Shields P, Chang-Claude J . Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008; 17(1):15-26. DOI: 10.1158/1055-9965.EPI-07-0598. View

Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K . CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res. 2005; 574(1-2):112-23. DOI: 10.1016/j.mrfmmm.2005.01.027. View

Drozdz M, Gierek T, Jendryczko A, Pilch J, Piekarska J . N-acetyltransferase phenotype of patients with cancer of the larynx. Neoplasma. 1987; 34(4):481-4. View

Johns L, Houlston R . N-acetyl transferase-2 and bladder cancer risk: a meta-analysis. Environ Mol Mutagen. 2000; 36(3):221-7. DOI: 10.1002/1098-2280(2000)36:3<221::aid-em5>3.0.co;2-q. View

10.

Marcus P, Vineis P, Rothman N . NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics. 2000; 10(2):115-22. DOI: 10.1097/00008571-200003000-00003. View

11.

Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L . A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis. 2008; 29(6):1164-9. DOI: 10.1093/carcin/bgn020. View

12.

Brockton N, Little J, Sharp L, Cotton S . N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol. 2000; 151(9):846-61. DOI: 10.1093/oxfordjournals.aje.a010289. View

13.

Wikman H, Bouchardy C, Mitrunen K, Dayer P, Benhamou S, Hirvonen A . Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers. Pharmacogenetics. 2000; 9(4):533-7. View

14.

Frank S . Genetic predisposition to cancer - insights from population genetics. Nat Rev Genet. 2004; 5(10):764-72. DOI: 10.1038/nrg1450. View

15.

Lei D, Pan X, Guo C, Xu F, Zhang L, Liu D . [Relationship between polymorphism of N-acetyltransferase 2 and genetic susceptibility to laryngeal carcinoma]. Zhonghua Zhong Liu Za Zhi. 2002; 24(2):154-6. View

16.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

17.

Borlak J, Reamon-Buettner S . N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med Genet. 2006; 7:58. PMC: 1533812. DOI: 10.1186/1471-2350-7-58. View

18.

Ochs-Balcom H, Wiesner G, Elston R . A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer. Am J Epidemiol. 2007; 166(3):246-54. DOI: 10.1093/aje/kwm066. View

19.

Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M, Kaneko K . Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer. 1999; 80(5):685-8. DOI: 10.1002/(sici)1097-0215(19990301)80:5<685::aid-ijc9>3.0.co;2-w. View

20.

Chen K, Jiang Q, He H . Relationship between metabolic enzyme polymorphism and colorectal cancer. World J Gastroenterol. 2005; 11(3):331-5. PMC: 4205331. DOI: 10.3748/wjg.v11.i3.331. View